Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 2, 2021Becomes the First Medical Technology Company Authorized as a CVE Numbering Authority
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has become the first medical technology company authorized as a Common...
-
May 26, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences during the...
-
May 26, 2021U.S. Launch of BD Kiestra™ Urine Culture Application Helps Accelerate Workflow and Drive Lab Efficiency
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra™ lab...
-
May 25, 2021BD Surgiphor™ sterile wound irrigation system delivers simplified sterility and helps hospitals comply with national and international guidelines[1,2]
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the availability of BD Surgiphor™ Sterile Wound Irrigation System, the first and only...
-
May 18, 2021New plant will produce drug delivery devices, employ 150 people in 2024 and up to 600 when full operations start in 2030
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will build a €165 million ($200 million USD) high-tech manufacturing facility in the city of...
-
May 13, 2021BD Onclarity™ HPV Assay CE Marked for Self-Collection; Available on BD Viper™ LT and BD COR™ Systems
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the industry's first self-collection claim for HPV screening has been CE marked to the...
-
May 6, 2021Standalone Diabetes Care business expected to leverage position as global leader in insulin delivery and expand presence in large and high-growth diabetes market
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized management to proceed with a plan to...
-
May 6, 2021- Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021....
-
Apr 29, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor healthcare conferences...
-
Apr 29, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market...